Biogen Inc. (BIIB)
NASDAQ: BIIB · IEX Real-Time Price · USD
230.93
+0.36 (0.16%)
May 20, 2024, 9:57 AM EDT - Market open
Biogen Employees
Biogen had 7,570 employees on December 31, 2023. The number of employees decreased by 1,155 or -13.24% compared to the previous year.
Employees
7,570
Change (1Y)
-1,155
Growth (1Y)
-13.24%
Revenue / Employee
$1,276,499
Profits / Employee
$154,108
Market Cap
33.57B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
Dec 31, 2022 | 8,725 | -885 | -9.21% |
Dec 31, 2021 | 9,610 | 510 | 5.60% |
Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
Dec 31, 2019 | 7,400 | -400 | -5.13% |
Dec 31, 2018 | 7,800 | 500 | 6.85% |
Dec 31, 2017 | 7,300 | -100 | -1.35% |
Dec 31, 2016 | 7,400 | 50 | 0.68% |
Dec 31, 2015 | 7,350 | -200 | -2.65% |
Dec 31, 2014 | 7,550 | 700 | 10.22% |
Dec 31, 2013 | 6,850 | 900 | 15.13% |
Dec 31, 2012 | 5,950 | 950 | 19.00% |
Dec 31, 2011 | 5,000 | 150 | 3.09% |
Dec 31, 2010 | 4,850 | 100 | 2.11% |
Dec 31, 2009 | 4,750 | 50 | 1.06% |
Dec 31, 2008 | 4,700 | 400 | 9.30% |
Dec 31, 2007 | 4,300 | 550 | 14.67% |
Dec 31, 2006 | 3,750 | 410 | 12.28% |
Dec 31, 2005 | 3,340 | -926 | -21.71% |
Dec 31, 2004 | 4,266 | 539 | 14.46% |
Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
Jan 31, 2003 | 995 | 303 | 43.79% |
Jan 31, 2002 | 692 | 199 | 40.37% |
Jan 31, 2001 | 493 | 86 | 21.13% |
Jan 31, 2000 | 407 | 42 | 11.51% |
Jan 31, 1999 | 365 | 26 | 7.67% |
Dec 31, 1997 | 339 | 71 | 26.49% |
Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Koninklijke Philips | 69,656 |
Centene | 67,000 |
GE HealthCare Technologies | 51,000 |
Takeda Pharmaceutical | 49,095 |
ICON PLC | 41,100 |
Haleon | 25,408 |
Mettler-Toledo International | 17,300 |
West Pharmaceutical Services | 10,600 |
BIIB News
- 3 days ago - Biogen and Ionis Pharma shares slide as they end development of ALS treatment - Market Watch
- 4 days ago - Biogen, Ionis to discontinue development of ALS drug - Reuters
- 4 days ago - Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis - GlobeNewsWire
- 4 days ago - Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis - PRNewsWire
- 5 days ago - Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status - GlobeNewsWire
- 18 days ago - Biogen Reports Progress on Corporate Responsibility Priorities - GlobeNewsWire
- 24 days ago - Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® - GlobeNewsWire
- 26 days ago - Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales - Barrons